EFFECT OF INTRAVENOUS ADMINISTRATION OF SECRETOME ON MALONDIALDEHYDE LEVELS IN ROTENONE-INDUCED PARKINSON'S DISEASE RATS
DOI:
https://doi.org/10.21776/ub.mnj.2025.011.01.03Keywords:
Lipid peroxidation, malondialdehyde, mesenchymal stem cell secretome, oxidative stress, Parkinson's DiseaseAbstract
Background: Parkinson's disease (PD) is a progressive neurodegenerative disorder with an increasing prevalence. Oxidative stress is known to contribute to the development of PD through lipid peroxidation, which causes damage to the substantia nigra pars compacta. Lipid peroxidation produces malondialdehyde (MDA), which is known to be elevated in PD patients. Up till now, there is no cure for PD, and the available therapies are only symptomatic. The secretome from Mesenchymal Stem Cell (MSC) has antioxidant and neuroprotective components, making it a potential therapeutic agent that may slow the progression of PD.
Objective: This study seeks to determine the effect of MSC secretome on oxidative stress in rotenone-induced PD rats.
Methods: This research was an in-vivo experiment conducted with 30 male Sprague Dawley rats, divided into sham control, rotenone (+) secretome (-), and rotenone (+) secretome (+) groups. Rotenone (2.75 mg/kgBW) was administered for seven days to induce a PD model. Secretome administration (1 mg/ml) was carried out on days 3, 5, and 7. MDA levels were determined using the sandwich ELISA method.
Results: This study found no significant difference in MDA levels among the three groups (p = 0.203). The sham control group had the lowest MDA 1.32(0.53) nmol/mL, followed by the rotenone (+) secretome (+) group 1.56(0.33) nmol/ml, and the highest MDA was observed in the rotenone (+) secretome (-) group 1.88(0.14) nmol/mL.
Conclusion: Administration of MSC secretome did not significantly cause changes in plasma MDA levels of rotenone-induced Parkinson Disease rats.
Downloads
References
Yamabe K, Liebert R, Flores N, Pashos C. Health-related quality-of-life, work productivity, and economic burden among patients with Parkinson's disease in Japan. J Med Econ; 2018. 21(12):1206–1212. DOI: 10.1080/13696998.2018.1522638.
Dorsey ER, Elbaz A, Nichols E, Abd-Allah F, Abdelalim A, Adsuar JC, et al. Global, regional, and national burden of Parkinson's disease, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol; 2018. 17(11):939–53. DOI: 10.1016/S1474-4422(18)30295-3.
Orozco JL, Valderrama-Chaparro JA, Pinilla-Monsalve GD, Molina-Echeverry MI, Pérez Castaño AM, Ariza-Araújo Y, et al. Parkinson's disease prevalence, age distribution and staging in Colombia. Neurol Int; 2020. 12(1):8401.
DOI: 10.4081/ni.2020.8401.
Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primer; 2017. 3:17013.
DOI: 10.1038/nrdp.2017.13.
Reeve A, Simcox E, Turnbull D. Ageing and Parkinson's disease: Why is advancing age the biggest risk factor? Ageing Res Rev; 2014. 14(100):19–30. DOI: 10.1016/j.arr.2014.01.004.
Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson's disease. J Park Dis; 2013. 3(4):461–91. DOI: 10.3233/JPD-130230.
de Farias CC, Maes M, Bonifácio KL, Bortolasci CC, de Souza Nogueira A, Brinholi FF, et al. Highly specific changes in antioxidant levels and lipid peroxidation in Parkinson's disease and its progression: Disease and staging biomarkers and new
drug targets. Neurosci Lett; 2016. 617:66–71. DOI: 10.1016/j.neulet.2016.02.011.
Trist BG, Hare DJ, Double KL. Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease. Aging Cell; 2019. 18(6):e13031.
DOI: 10.1111/acel.13031
Ayala A, Muñoz MF, Argüelles S. Lipid peroxidation: Production, metabolism, and signaling mechanisms of malondialdehyde and 4-Hydroxy-2-Nonenal. Oxid Med Cell Longev; 2014. 2014:360438. DOI: 10.1155/2014/360438.
Guo JD, Zhao X, Li Y, Li GR, Liu XL. Damage to dopaminergic neurons by oxidative stress in Parkinson's disease (Review). Int J Mol Med; 2018. 41(4):1817–25. DOI: 10.3892/ijmm.2018.3406.
Angelova PR, Horrocks MH, Klenerman D, Gandhi S, Abramov AY, Shchepinov MS. Lipid peroxidation is essential for α-synuclein-induced cell death. J Neurochem; 2015. 133(4):582–9.
DOI: 10.1111/jnc.13024.
d'Angelo M, Cimini A, Castelli V. Insights into the effects of mesenchymal stem cell-derived secretome in Parkinson's disease. Int J Mol Sci; 2020. 21(15):5241. DOI: 10.3390/ijms21155241.
Teixeira FG, Carvalho MM, Panchalingam KM, Rodrigues AJ, Bárbara M. Impact of the secretome of human mesenchymal stem cells on brain structure and animal behavior in a rat model of Parkinson's disease; 2017. 6(2):634-646.
DOI: 10.5966/sctm.2016-0071.
Farfán N, Carril J, Redel M, Zamorano M, Araya M, Monzón E, et al. Intranasal administration of mesenchymal stem cell secretome reduces hippocampal oxidative stress, neuroinflammation and cell death, improving the behavioral outcome following perinatal asphyxia. Int J Mol Sci; 2020. 21(20):7800. DOI: 10.3390/ijms21207800.
Venugopal C, Prasad YSHC, Shobha K, Pinnelli VB, Dhanushkodi A. HEK-293 secretome attenuates kainic acid neurotoxicity through insulin like growth factor-phosphatidylinositol-3-kinases pathway and by temporal regulation of antioxidant defense machineries. NeuroToxicology; 2018. 69:189–200. DOI: 10.1016/j.neuro.2017.11.010.
Abdel-Salam OME, Youssef Morsy SM, Youness ER, Yassen NN, Sleem AA. The effect of low dose amphetamine in rotenone-induced toxicity in a mice model of Parkinson's disease. Iran J Basic Med Sci; 2020. 23(9):1207–17.
DOI: 10.22038/ijbms.2020.45175.10524.
Bandookwala M, Sahu AK, Thakkar D, Sharma M, Khairnar A, Sengupta P. Edaravone-caffeine combination for the effective management of rotenone induced Parkinson's disease in rats: An evidence based affirmative from a comparative analysis of behavior and biomarker expression. Neurosci Lett; 2019. 711:134438.
DOI: 10.1016/j.neulet.2019.134438.
Yang J, Liu XX, Fan H, Tang Q, Shou ZX, Zuo DM, et al. Extracellular vesicles derived from bone marrow mesenchymal stem cells protect against experimental colitis via attenuating colon inflammation, oxidative stress and apoptosis. PloS One; 2015. 10(10):e0140551.
DOI: 10.1371/journal.pone.0140551.
Pérez-Rodríguez L, Romero-Haro AA, Sternalski A, Muriel J, Mougeot F, Gil D, et al. Measuring oxidative stress: The confounding effect of lipid concentration in measures of lipid peroxidation. Physiol Biochem Zool PBZ; 2015. 88(3):345–51. DOI: 10.1086/680688.
Yang RL, Shi YH, Hao G, Li W, Le GW. Increasing oxidative stress with progressive hyperlipidemia in human: Relation between malondialdehyde and atherogenic index. J Clin Biochem Nutr; 2008. 43(3):154–8. DOI: 10.3164/jcbn.2008044.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 MNJ (Malang Neurology Journal)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.